»
«
Offline Showroom in USA
Post Offer Free
MOSINTER GROUP LIMITED
MOSINTER GROUP LIMITED

China BIBW2992 CAS 439081-18-2 BIBW 2992 BIBW-2992 Tovok Afatinib manufacturer

5th

Gold Index: 88452

You are here: home  > Pharmaceutical Chemicals API  > Antineoplastic Drugs API  > BIBW2992 CAS 439081-18-2 BIBW 2992 BIBW-2992 Tovok Afatinib

BIBW2992 CAS 439081-18-2 BIBW 2992 BIBW-2992 Tovok Afatinib 

Payment Terms: T/T,L/C,WU 
Place of Origin: Shandong, China (Mainland) 
inquire skype
Add to My Favorites
HiSupplier Escrow
Share |

Product Detail

Means of Transport: Ocean,Land,Air
Packing: According to the request of...
Molecular Formula: C24H25ClFN5O3
Specification: CP/USP/EP
Density: 1.381g/cm3
Boiling point: 676.917°C at 760 mmHg
Production Capacity: 10 KG/Year
Delivery Date: within 7 days
Molecular Weight: 485.94
Content: 98%min
Flashing point: 363.186°C
Vapour pressure: 0mmHg at 25°C

Afatinib (INN; trade name Gilotrif in the US and Giotrif in Europe, previously Tomtovok and Tovok ) is a drug approved in much of the world

BIBW2992 (CAS: 439081-18-2)


Item

Index

Molecular Formula

C24H25ClFN5O3

Molecular Weight

485.94

Specification

CP/USP/EP

Content

98%min

Afatinib (INN; trade name Gilotrif in the US and Giotrif in Europe, previously Tomtovok and Tovok ) is a drug approved in much of the world (including the United States, Canada, the United Kingdom and Australia) for the treatment of metastatic non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim. It acts as an angiokinase inhibitor.

Medical uses

It has received regulatory approval for use as a treatment for non-small cell lung cancer, although there is emerging evidence to support its use in other cancers such as breast cancer.

In October 2010 a Phase III trial in NSCLC patients called Lux-Lung 5 began with this drug. Fall 2010 interim results suggested the drug extendedprogression-free survival threefold compared to placebo, but did not extend overall survival. In May 2012, the Phase IIb/III trial Lux-Lung 1 came to the same conclusion.

Phase II results for breast cancer that over-expresses the protein human epidermal growth factor receptor 2 (Her2-positive breast cancer) were described as promising by the authors, with 19 of 41 patients achieving benefit from afatinib. Double-blind Phase III trials are under way to confirm or refute this finding. Her2-negative breast cancers showed limited or no response to the drug.


bigPhoto
skype Mr. Fedor

Tel: +86-574-89212210
Fax: +86-574-89212215
Mobile: 86- 189 8930 5995
Contact to this supplier

Didn't find what you're looking for? Post Buying Lead or contact HiSupplier Customer Service Center  for help!

Related Search

Find more related products in following catalogs on Hisupplier.com

Other products from this supplier

Company Info

MOSINTER GROUP LIMITED [China (Mainland)]

sgs ico Offline Showroom in USA

Business Type:Manufacturer, Trading Company
City: Ningbo
Province/State: Zhejiang
Country/Region: China (Mainland)

Follow Us: Follow us on facebook Follow us on linkedin

Fedor:   skype

You May Like: